Mediators of Inflammation

Mediators of Inflammation / 2004 / Article

Open Access

Volume 13 |Article ID 453145 | https://doi.org/10.1080/09637480400003022

Rita L. Cardoni, María Inés Antúnez, "Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections", Mediators of Inflammation, vol. 13, Article ID 453145, 6 pages, 2004. https://doi.org/10.1080/09637480400003022

Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections

Abstract

TRYPANOSOMA cruzi induces inflammatory reactions in several tissues. The production of prostaglandin F, 6-keto-prostaglandin F and thromboxane B2, known to regulate the immune response and to participate in inflammatory reactions, was studied in mice experimentally infected with T. cruzi. The generation of nitric oxide (NO), which could be regulated by cyclooxygenase metabolites, was also evaluated. In the acute infection the extension of inflammatory infiltrates in skeletal muscle as well as the circulating levels of cyclooxygenase metabolites and NO were higher in resistant C3H mice than in susceptible BALB/c mice. In addition, the spontaneous release of NO by spleen cells increased earlier in the C3H mouse strain. In the chronic infections, the tissue inflammatory reaction was still prominent in both groups of mice, but a moderate increase of thromboxane B2 concentration and in NO released by spleen cells was observed only in C3H mice. This comparative study shows that these mediators could be mainly related to protective mechanisms in the acute phase, but seem not to be involved in its maintenance in the chronic T. cruzi infections.

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views81
Downloads372
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.